Checkpoint inhibition and melanoma: Considerations in treating the older adult

Extermann, 2007, Interaction between comorbidity and cancer, Cancer Control, 14, 13, 10.1177/107327480701400103 Kendal, 2008, Dying with cancer: the influence of age, comorbidity, and cancer site, Cancer, 112, 1354, 10.1002/cncr.23315 Jemal, 2011, Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006, J Am Acad Dermatol, 65, e11 Macdonald, 2011, Malignant melanoma in the elderly: different regional disease and poorer prognosis, J Cancer Educ, 2 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 10.1056/NEJMoa1003466 Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, 364, 10.1056/NEJMoa1104621 Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, 372, 320, 10.1056/NEJMoa1412082 Robert, 2014, Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial, Lancet, 384, 1109, 10.1016/S0140-6736(14)60958-2 Robert, 2015, Pembrolizumab versus Ipilimumab in advanced melanoma, N Engl J Med, 372, 2521, 10.1056/NEJMoa1503093 Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med, 373, 23, 10.1056/NEJMoa1504030 Postow, 2015, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N Engl J Med, 372, 2006, 10.1056/NEJMoa1414428 Tomihara, 2013, Optimization of immunotherapy in elderly cancer patients, Crit Rev Oncog, 18, 573, 10.1615/CritRevOncog.2013010591 Fulop, 2013, Immunosenescence and cancer, Crit Rev Oncog, 18, 489, 10.1615/CritRevOncog.2013010597 Bandaranayake, 2016, Host resistance and immune aging, Clin Geriatr Med, 32, 415, 10.1016/j.cger.2016.02.007 Kubo, 1990, Polymorphism of age-related changes in interleukin (IL) production: differential changes of T helper subpopulations, synthesizing IL 2, IL3 and IL4, Eur J Immunol, 20, 1289, 10.1002/eji.1830200614 Bloom, 1990, Age-related decrement in cytotoxic T lymphocyte (CTL) activity is associated with decreased levels of mRNA encoded by two CTL-associated serine esterase genes and the perforin gene in mice, Eur J Immunol, 20, 2309, 10.1002/eji.1830201021 Britanova, 2014, Age-related decrease in TCR repertoire diversity measured with deep and normalized sequence profiling, J Immunol, 192, 2689, 10.4049/jimmunol.1302064 N-p, 2009, CD28−T cells: their role in the age-associated decline of immune function, Trends Immunol, 30, 306, 10.1016/j.it.2009.03.013 Nishijima, 2016, Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis, Cancer Treat Rev, 45, 30, 10.1016/j.ctrv.2016.02.006 Funakoshi, 2016, Abstract A159: comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a meta-analysis of randomized controlled trials, Cancer Immunol Res, 4, A159, 10.1158/2326-6074.CRICIMTEATIAACR15-A159 Chiarion Sileni, 2014, Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme, J Exp Clin Cancer Res, 33, 1, 10.1186/1756-9966-33-30 Elias, 2016, Immune checkpoint inhibitors in older adults, Curr Oncol Rep, 18, 47, 10.1007/s11912-016-0534-9 Hodi, 2015, Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study, 33, 9004 FDA, 2001 Opdivo (R) [package insert], 2014 Yervoy (R) [package insert], 2011 Weber, 2012, Management of immune-related adverse events and kinetics of response with ipilimumab, J Clin Oncol, 30, 2691, 10.1200/JCO.2012.41.6750 Fecher, 2013, Ipilimumab and its toxicities: a multidisciplinary approach, Oncologist, 18, 733, 10.1634/theoncologist.2012-0483 Corsello, 2013, Endocrine side effects induced by immune checkpoint inhibitors, J Clin Endocrinol Metab, 98, 1361, 10.1210/jc.2012-4075 Ryder, 2014, Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution, Endocr Relat Cancer, 21, 371, 10.1530/ERC-13-0499 Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med, 373, 23, 10.1056/NEJMoa1504030 Martin-Liberal, 2015, Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report, Cancer Immunol Immunother, 64, 765, 10.1007/s00262-015-1689-1 Hamid, 2011, A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma, J Transl Med, 9, 204, 10.1186/1479-5876-9-204 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Weber, 2015, Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis, 33, 9018 Friedman, 2016, Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80+), 34, 10009 Ferris, 2016, Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N Engl J Med, 375, 1856, 10.1056/NEJMoa1602252 Borson, 2000, The mini-cog: a cognitive 'vital signs' measure for dementia screening in multi-lingual elderly, Int J Geriatr Psychiatry, 15, 1021, 10.1002/1099-1166(200011)15:11<1021::AID-GPS234>3.0.CO;2-6 Soubeyran, 2012, Predictors of early death risk in older patients treated with first-line chemotherapy for cancer, J Clin Oncol, 30, 1829, 10.1200/JCO.2011.35.7442 Friedman, 2017, Toxicity associated with ipilimumab and nivolumab (Ipi+Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP), ASCO Meeting Abstracts, 34, 9519 2011 Horvat, 2015, Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering Cancer Center, J Clin Oncol, 33, 3193, 10.1200/JCO.2015.60.8448 Malmrose, 1993, Measured versus estimated creatinine clearance in a high-functioning elderly sample: MacArthur Foundation study of successful aging, J Am Geriatr Soc, 41, 715, 10.1111/j.1532-5415.1993.tb07459.x Davies, 1995, Age-associated alterations in thirst and arginine vasopressin in response to a water or sodium load, Age Ageing, 24, 151, 10.1093/ageing/24.2.151 Bourdel-Marchasson, 2004, One-year incidence of hyperosmolar states and prognosis in a geriatric acute care unit, Gerontology, 50, 171, 10.1159/000076775 Mellati, 2015, Anti-PD-1 and anti-PDL-1 monoclonal antibodies causing type 1 diabetes, Diabetes Care, 38, e137, 10.2337/dc15-0889 Dubovsky, 2012, The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited, Psychosomatics, 53, 103, 10.1016/j.psym.2011.12.007